Svetlana P. Chapoval, MD, PhD

Russian State Medical University, MD, 1985

Gamaleya Scientific Research Institute of Epidemiology and Microbiology, PhD, 1994

Mayo Clinic and Foundation, Fellowship, Immunology, 2002

Svetlana Chapoval, MD, PhD has developed and led a research project focused on neuroimmune semaphorins 4A and 4D as novel regulators and therapeutic targets in allergic asthma.

Dr. Chapoval completed her postdoctoral training under a mentorship of Dr. Chella David in the Department of Immunology at Mayo Clinic in Rochester, MN. Her research was aimed to delineate the association of the HLA Class II polymorphism with allergic asthma susceptibility. Subsequently, she joined the faculty of the Department of Pulmonary and Critical Care Medicine at Yale University as an Associate Research Scientist.

While at Yale, Dr. Chapoval participated in several collaborative projects defining the roles of selected Th cytokines and growth factors in cellular and molecular mechanisms underlying chronic lung inflammatory diseases. She joined the Department of Microbiology and Immunology of the University of Maryland School of Medicine in 2006 as an Assistant Professor with a research position at the Center for Vascular and Inflammatory Diseases. She is a member of the Program in Oncology at the Greenebaum Comprehensive Cancer Center.

Dr. Chapoval has served and continue to serve as a reviewer for 20+ peer-reviewed scientific journals. In 2015, she completed a 4-year term as an Associate Editor for the Journal of Immunology. During her career Dr. Chapoval received multiple travel grant awards from the American Academy of Allergy, Asthma and Immunology and the American Association of Immunologists for research presentations at the society’s meetings. She was a member of two NIH/NIAID scientific review groups.

neuroimmune semaphorins 4A and 4D, Center for Vascular and Inflammatory Diseases

Chapoval SP, Hritzo M, Qi X, Tamagnone L, Golding A, Keegan AD. (2019) Semaphorin 4A stabilizes human Treg cell phenotype via Plexin B1. ImmunoHorizons, 3:71-87.

Chapoval SP, Z Vadasz, AI Chapoval, E Toubi. (2017) Semaphorins 4A and 4D in chronic inflammatory diseases. Inflammation Research. 66:111-117.

Chapoval SP. (2015) Semaphorin 4A as novel regulator and promising therapeutic target in rheumatoid arthritis. Arthritis Research and Therapy.17:313.

Mogie G, K Shanks, EH Nkyimbeng-Takwi, EP Smith, E Davila, MM Lipsky, LJ DeTolla, AD Keegan, SP Chapoval. (2013) Neuroimmune semaphorin 4A as a drug and drug target for asthma. International Immunopharmacology.17:568-575.

Shanks K, EH Nkyimbeng-Takwi, EP Smith, MM Lipsky, LJ DeTolla, AD Keegan, SP Chapoval. (2013) Neuroimmune semaphorin 4D is necessary for optimal lung allergic inflammation. Molecular Immunology. 56:480-487

Nkyimbeng-Takwi EH, K Shanks, Smith EP, A Iyer, MM Lipsky, LJ DeTolla, H Kikutani, AD Keegan, SP Chapoval. (2012) Neuroimmune semaphorin 4A downregulates the severity of allergic response. Mucosal Immunology. 5:409-419.

Smith EP, K Shanks, MM Lipsky, LJ DeTolla,AD Keegan, SP Chapoval. (2011) Expression of neuroimmune semaphorins 4A and 4D and their receptors in the lung is enhanced by allergen and vascular endothelial growth factor. BMC Immunology. 12:30.